Pharmacokinetics of the systemic application of hyaluronic acid
for joint arthritis treatment

J 2025

Pharmacokinetics of the systemic application of hyaluronic acid for joint arthritis treatment

SIMEK, Matej; Daniela RUBANOVÁ; Kristina NESPOROVA; Svitlana SKOROPLYAS; Katerina LEHKA et al.

Základní údaje

Originální název

Pharmacokinetics of the systemic application of hyaluronic acid for joint arthritis treatment

Autoři

SIMEK, Matej; Daniela RUBANOVÁ; Kristina NESPOROVA; Svitlana SKOROPLYAS; Katerina LEHKA; Petra RAPTOVÁ; Vladimir VELEBNY a Lukáš KUBALA

Vydání

International Journal of Biological Macromolecules, Elsevier B.V. 2025, 0141-8130

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10608 Biochemistry and molecular biology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 8.500 v roce 2024

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14310/25:00142031

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova anglicky

Hyaluronan; Rheumatoid arthritis; Pharmacokinetics; Stable isotope; Intravenous; Intraperitoneal; Inflammation; Vascular leakage

Štítky

14314010, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 1. 12. 2025 10:02, Mgr. Marie Novosadová Šípková, DiS.

Anotace

V originále

Frequent degenerative joint diseases, known as arthritis, are characterized by joint inflammation and cartilage breakdown. Various arthritis types are traditionally managed with intraarticular injections of hyaluronan or its derivatives. However, intravenous administration of hyaluronan is emerging as a vital alternative, particularly because intraarticular injections can be challenging for clinicians when targeting small or swollen joints. Pharmacokinetics of intravenously and intraperitoneally administered middle-Mw hyaluronan were studied in an adjuvant-induced arthritis mouse model alongside therapeutic effects. Using 13C-, biotin- and fluoresce-labeling, we found hyaluronan accumulated in inflamed joint tissues while distribution in other organs remained similar to healthy controls. Repeated administrations significantly reduced arthritis symptoms like swelling and redness, RANKL, inducible nitric oxide synthase, COMP and prostaglandin E2 levels. Moreover, hyaluronan treatment prevented dextran-FITC penetration into inflamed paws suggesting reduced vascular permeability at the site of inflammation. These findings support systemic hyaluronan administration as a promising arthritis treatment strategy.

Citovat

SIMEK, Matej; Daniela RUBANOVÁ; Kristina NESPOROVA; Svitlana SKOROPLYAS; Katerina LEHKA; Petra RAPTOVÁ; Vladimir VELEBNY a Lukáš KUBALA. Pharmacokinetics of the systemic application of hyaluronic acid for joint arthritis treatment. International Journal of Biological Macromolecules. Elsevier B.V., 2025, roč. 307, May, s. 141937-141946. ISSN 0141-8130. Dostupné z: https://doi.org/10.1016/j.ijbiomac.2025.141937.

@article{2518757,
   author = {Simek, Matej and Rubanová, Daniela and Nesporova, Kristina and Skoroplyas, Svitlana and Lehka, Katerina and Raptová, Petra and Velebny, Vladimir and Kubala, Lukáš},
   article_number = {May},
   doi = {https://doi.org/10.1016/j.ijbiomac.2025.141937},
   keywords = {Hyaluronan; Rheumatoid arthritis; Pharmacokinetics; Stable isotope; Intravenous; Intraperitoneal; Inflammation; Vascular leakage},
   language = {eng},
   issn = {0141-8130},
   journal = {International Journal of Biological Macromolecules},
   title = {Pharmacokinetics of the systemic application of hyaluronic acid for joint arthritis treatment},
   url = {https://www.sciencedirect.com/science/article/pii/S0141813025024882?via%3Dihub},
   volume = {307},
   year = {2025}
}

TY  - JOUR
ID  - 2518757
AU  - Simek, Matej - Rubanová, Daniela - Nesporova, Kristina - Skoroplyas, Svitlana - Lehka, Katerina - Raptová, Petra - Velebny, Vladimir - Kubala, Lukáš
PY  - 2025
TI  - Pharmacokinetics of the systemic application of hyaluronic acid for joint arthritis treatment
JF  - International Journal of Biological Macromolecules
VL  - 307
IS  - May
SP  - 141937
EP  - 141937
PB  - Elsevier B.V.
SN  - 01418130
KW  - Hyaluronan
KW  - Rheumatoid arthritis
KW  - Pharmacokinetics
KW  - Stable isotope
KW  - Intravenous
KW  - Intraperitoneal
KW  - Inflammation
KW  - Vascular leakage
UR  - https://www.sciencedirect.com/science/article/pii/S0141813025024882?via%3Dihub
N2  - Frequent degenerative joint diseases, known as arthritis, are characterized by joint inflammation and cartilage breakdown. Various arthritis types are traditionally managed with intraarticular injections of hyaluronan or its derivatives. However, intravenous administration of hyaluronan is emerging as a vital alternative, particularly because intraarticular injections can be challenging for clinicians when targeting small or swollen joints. Pharmacokinetics of intravenously and intraperitoneally administered middle-Mw hyaluronan were studied in an adjuvant-induced arthritis mouse model alongside therapeutic effects. Using 13C-, biotin- and fluoresce-labeling, we found hyaluronan accumulated in inflamed joint tissues while distribution in other organs remained similar to healthy controls. Repeated administrations significantly reduced arthritis symptoms like swelling and redness, RANKL, inducible nitric oxide synthase, COMP and prostaglandin E2 levels. Moreover, hyaluronan treatment prevented dextran-FITC penetration into inflamed paws suggesting reduced vascular permeability at the site of inflammation. These findings support systemic hyaluronan administration as a promising arthritis treatment strategy.
ER  -

SIMEK, Matej; Daniela RUBANOVÁ; Kristina NESPOROVA; Svitlana SKOROPLYAS; Katerina LEHKA; Petra RAPTOVÁ; Vladimir VELEBNY a Lukáš KUBALA. Pharmacokinetics of the systemic application of hyaluronic acid for joint arthritis treatment. \textit{International Journal of Biological Macromolecules}. Elsevier B.V., 2025, roč.~307, May, s.~141937-141946. ISSN~0141-8130. Dostupné z: https://doi.org/10.1016/j.ijbiomac.2025.141937.

Přehled o publikaci